What do systematic reviews say?

Intervention not reported

• Stretching to prevent or reduce muscle soreness after exercise 2011 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 158 participants
  Low

Intervention not reported

• Stretching to prevent or reduce muscle soreness after exercise 2011 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 197 participants
  Low

Intervention not reported

• Stretching to prevent or reduce muscle soreness after exercise 2011 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 198 participants
  Low

SPECIALISED TEAM vs usual care

• Early intervention for psychosis 2011 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 547 participants
  Moderate

Intervention not reported

• Creatine and creatine analogues in hypertension and cardiovascular disease 2011 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 13 participants
  Low

Intervention not reported

• Creatine and creatine analogues in hypertension and cardiovascular disease 2011 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 13 participants
  Low

Intervention not reported

• Creatine and creatine analogues in hypertension and cardiovascular disease 2011 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 17 participants
  Low

Intervention not reported

• Creatine and creatine analogues in hypertension and cardiovascular disease 2011 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 79 participants
  Low

Intervention not reported

• Creatine and creatine analogues in hypertension and cardiovascular disease 2011 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 88 participants
  Low

Factor Xa inhibitors vs Anticoagulants

Factor Xa inhibitors showed no clear difference in all causes of mortality at 30 days compared with anticoagulants (high certainty).

• Factor Xa inhibitors for acute coronary syndromes 2011 · Cochrane Headline outcomes only
  RR 0.9 [0.8, 1.01]
  4 studies · 27976 participants
  High

Factor Xa inhibitors vs Anticoagulants

Factor Xa inhibitors showed no clear difference in all causes of mortality at 30 days ‐ UFH compared with anticoagulants (high certainty).

• Factor Xa inhibitors for acute coronary syndromes 2011 · Cochrane Headline outcomes only
  RR 0.98 [0.82, 1.18]
  2 studies · 6760 participants
  High

Factor Xa inhibitors vs Anticoagulants

Factor Xa inhibitors leads to lower all causes of mortality at 30 days ‐ Enoxaparin compared with anticoagulants (high certainty).

• Factor Xa inhibitors for acute coronary syndromes 2011 · Cochrane Headline outcomes only
  RR 0.85 [0.73, 0.98]
  2 studies · 21216 participants
  High

Factor Xa inhibitors vs Anticoagulants

Factor Xa inhibitors showed no clear difference in major bleeding at 30 days compared with anticoagulants (high certainty).

• Factor Xa inhibitors for acute coronary syndromes 2011 · Cochrane Headline outcomes only
  RR 1.01 [0.98, 1.04]
  2 studies · 20404 participants
  High
• Factor Xa inhibitors for acute coronary syndromes 2011 · Cochrane Headline outcomes only
  RR 0.98 [0.92, 1.04]
  1 study · 326 participants
  High

Factor Xa inhibitors vs Anticoagulants

Factor Xa inhibitors leads to higher major bleeding at 30 days ‐ Enoxaparin compared with anticoagulants (high certainty).

• Factor Xa inhibitors for acute coronary syndromes 2011 · Cochrane Headline outcomes only
  RR 1.02 [1.01, 1.02]
  1 study · 20078 participants
  High

Factor Xa inhibitors vs Anticoagulants

Factor Xa inhibitors showed no clear difference in minor bleeding at 30 days compared with anticoagulants (high certainty).

• Factor Xa inhibitors for acute coronary syndromes 2011 · Cochrane Headline outcomes only
  RR 0.7 [0.14, 3.39]
  2 studies · 20404 participants
  High
• Factor Xa inhibitors for acute coronary syndromes 2011 · Cochrane Headline outcomes only
  RR 1.76 [0.52, 5.94]
  1 study · 326 participants
  Moderate
• Factor Xa inhibitors for acute coronary syndromes 2011 · Cochrane Headline outcomes only
  RR 0.34 [0.28, 0.43]
  1 study · 20078 participants
  High

Primary analyses ERAS vs conventional

• Fast track surgery versus conventional recovery strategies for colorectal surgery 2011 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 237 participants
  Very low

Intervention vs control

It is very uncertain whether intervention changes 60‐day mortality ‐ Aprotinin versus control compared with control (very low certainty).

• Methods to decrease blood loss and transfusion requirements for liver transplantation 2011 · Cochrane Headline outcomes only
  RR 0.52 [0.18, 1.45]
  3 studies · 280 participants
  Very low

Intervention vs control

It is very uncertain whether intervention changes 60‐day mortality ‐ Tranexamic acid versus control compared with control (very low certainty).

• Methods to decrease blood loss and transfusion requirements for liver transplantation 2011 · Cochrane Headline outcomes only
  RR 0.55 [0.17, 1.76]
  3 studies · 139 participants
  Very low

Intervention vs control

It is very uncertain whether intervention changes 60‐day mortality ‐ Recombinant factor VIIa (rFVIIa) versus control compared with control (very low certainty).

• Methods to decrease blood loss and transfusion requirements for liver transplantation 2011 · Cochrane Headline outcomes only
  RR 1.51 [0.33, 6.95]
  3 studies · 286 participants
  Very low

Intervention vs control

It is very uncertain whether intervention changes 60‐day mortality ‐ Tranexamic acid versus aprotinin compared with control (very low certainty).

• Methods to decrease blood loss and transfusion requirements for liver transplantation 2011 · Cochrane Headline outcomes only
  RR 4.12 [0.71, 23.76]
  2 studies · 178 participants
  Very low